Context Therapeutics is trading at $0.28, down 7.63% in pre-market, with no clear overnight company-specific catalyst identified.
- The company’s investor-relations page lists its latest release as September 9, announcing the first patient dosed in its CT-202 Phase 1 trial—not a new October 12 announcement.
- Major U.S. indices are mixed and near flat, so broad-market sentiment does not clearly explain the decline.
- No pre-market volume or activity data was provided.